Sleep Apnea

4
Pipeline Programs
4
Companies
5
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
3
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Apnimed
ApnimedMA - Cambridge
2 programs
1
1
SivopixantPhase 21 trial
SAS0421aPhase 1/21 trial
Active Trials
NCT03892772CompletedEst. Jul 2021
NCT06776432RecruitingEst. Dec 2025
Takeda
TakedaTOKYO, Japan
1 program
1
DanavorextonPhase 21 trial
Active Trials
NCT05814016Terminated41Est. Sep 2024
E
EisaiChina - Liaoning
1 program
1
ZonisamidePhase 21 trial
Active Trials
NCT01765608Completed50Est. Jun 2013
Zoll
ZollCA - San Jose
1 program
Dual Channel StimulationN/A1 trial
Active Trials
NCT06556693RecruitingEst. Dec 2034

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
ApnimedSivopixant
TakedaDanavorexton
EisaiZonisamide
ApnimedSAS0421a
ZollDual Channel Stimulation

Clinical Trials (5)

Total enrollment: 91 patients across 5 trials

Safety and Efficacy Study of Sivopixant, Acetazolamide and SASS-001 in Sleep Apnea

Start: Apr 2025Est. completion: Dec 2025
Phase 2Recruiting
NCT05814016TakedaDanavorexton

A Study of Danavorexton in People With Obstructive Sleep Apnea After General Anesthesia for Abdominal Surgery

Start: May 2023Est. completion: Sep 202441 patients
Phase 2Terminated

Zonisamide for the Treatment of Obstructive Sleep Apnea in Overweight/Obese Patients

Start: Mar 2010Est. completion: Jun 201350 patients
Phase 2Completed

Combination Pharmacological Interventions for Multiple Mechanisms of Obstructive Sleep Apnea

Start: Jan 2019Est. completion: Jul 2021
Phase 1/2Completed
NCT06556693ZollDual Channel Stimulation

Janus II Feasibility

Start: Aug 2025Est. completion: Dec 2034
N/ARecruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 actively recruiting trials targeting 91 patients
4 companies competing in this space